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timulation and IL-4, IL-2, and rapamycin. Differential in gene
expression proﬁle was conﬁrmed during trial implementa-
tion (n¼39 T-Rapa12 and T-Rapa6 products evaluated). As in
the initial trial, T-Rapa6 cells were infused at d14 post-HCT
(2.5 x 107 cells/kg). Patients (pts; n¼44) received outpatient
chemotherapy (until CD4 < 200 cells/ml) and then received
an HLA-matched sibling mobilized allograft. GVHD prophy-
laxis was cyclosporine plus short-course sirolimus (to d14
post-HCT); low-intensity conditioning was ﬂudarabine (120
mg/m2) and cyclophosphamide (1200 mg/m2). Relative to T-
Rapa12 pts, T-Rapa6 pts had similar characteristics (Table I):
36/44 (81.8%) of T-Rapa6 pts had a diagnosis at highest risk
for disease progression (Kahl III) and/or were chemotherapy
refractory (stable or progressive disease to last regimen).
Similar to T-Rapa12 pts, mixed chimerism existed prior to T-
Rapa6 DLI (median T and myeloid chimerism at d14 post-
HCT: 44% and 35%, respectively). Similar to T-Rapa12 pts,
T-Rapa6 pts had a rapid increase in donor chimerism by d28
post-HCT with continued advancement towards full donor
chimerism by d100 post-HCT. Relative to T-Rapa12 pts, T-
Rapa6 pts had an increased frequency of acute GVHD at days
100 and 180 post-HCT; this increase was primarily attribut-
able to steroid-responsive gut disease. Chronic GVHD inci-
dence did not appear to be substantially increased in T-Rapa6
pts. T-Rapa6 and T-Rapa12 pts had similar survival probabil-
ities and frequency of sustained complete remission; in each
cohort, deaths were primarily due to progressive disease.
These data provide further support for evaluation of T-Rapa
cell pre-emptive DLI after low-intensity allogeneic HCT as
this approach associates with consistent alloengraftment,
sustained complete remissions, and low transplant-related
mortality. The differential gene expression proﬁle existent
between T-Rapa12 and T-Rapa6 cells is sufﬁcient to drive
differential acute GVHD effects.178
Extending the Option of CMV-Speciﬁc T Cells from the
CMV-Seronegative Donor
Patrick J. Hanley 1, Sarah Nikiforow 2, Jan Melenhorst 3,
Phillip Scheinberg 4, Barbara Savoldo 5, Gianpietro Dotti 6,
Cliona M. Rooney 7, Helen E. Heslop 8, Elizabeth J. Shpall 9,
A. John Barrett 10, Catherine M. Bollard 1,6. 1 Center for Cancer
and Immunology Research, Children’s National Medical Center,
Washington, DC; 2Hematologic Malignancies, Dana-Farber
Cancer Institute, Boston, MA; 3Hematology, National Institutes
of Health, National Heart, Lung, and Blood Institute, Bethesda,
MD; 4 Antonio Ermirio de Moraes Oncology Center, Hospital
Beneﬁcência Portuguesa de São Paulo, Sao Paulo, Brazil; 5 Texas
Children’s Hospital, Houston, TX; 6 Center for Cell and Gene
Therapy, Baylor College of Medicine, Houston, TX; 7 Center for
Cell and Gene Therapy, Dept. of Pediatrics, Dept. of Molecular
Virology and Microbiology, Baylor College of Medicine, Houston
Methodist Hospital and Texas Children’s Hospital, Houston, TX;
8 Center for Cell and Gene Therapy, Baylor College of Medicine,
Texas Children’s Hospital, The Methodist Hospital, Houston, TX;
9 Stem Cell Transplantation and Cellular Therapy, The
University of Texas MD Anderson Cancer Center, Houston, TX;
10Hematology Branch, National Heart, Lung, and Blood
Institute, Bethesda, MD
Adoptive transfer of CMVpp65-speciﬁc T-cells(cCTL) from
CMV-seropositive(CMVpos) donors effectively restores anti-
viral-immunity after stem cell transplantation. However, the
naïve T-cells in cord blood(CB) and adult CMV-seronegati-
ve(CMVneg) donors require different culture systems togenerate cCTL. With a novel GMP-applicable protocol we
have reliably generated cCTL from CB and found that 15/15
CB T-cell lines recognized atypical epitopes of pp65. We then
expanded cCTL from CMVneg donors in a GMP-applicable
way by isolating naive T-cells and stimulating them with
pp65-Pepmix-pulsed antigen-presenting cells supple-
mented with IL2,IL7,IL12, and IL15. cCTL expanded from 8/11
CMVneg donors were primarily CD8+ T-cells(mean 71%).
cCTL secreted IFN-g in response to pp65-peptides(mean 224
spots) as measured in Elispot assays and lysed pp65-pulsed
target cells. cCTL derived from naive T-cells recognized only
novel and atypical pp65 epitopes (e.g. LQTGIHVR,MLNIP-
SINV) but not the typical epitope NLVPMVATV as conﬁrmed
by ELISPOT and Pentamer. Analysis of the avidity of naïve
donor CTL speciﬁc for the atypical CMV epitopes revealed
that the 1/2 -maximum effective concentration was similar
(mean:600pM) to CMVpos CTL recognizing typical epito-
pes(mean: 300pM), and more avid than CMVpos CTL
recognizing atypical epitopes(mean:4nM). TCR sequencing
performed on T-cells speciﬁc for typical(CMVpos) and aty-
pical(CMVpos,CMVneg, and CB) epitopes revealed that
CMVpos donor cCTL recognizing typical epitopes were
markedly less polyclonal. To address the concern that atyp-
ical epitopes might not be naturally presented by CMV-
infected cells and therefore not recognized by in vitro
generated CTL, we tested whether cCTL generated using CMV
AD169-infected ﬁbroblasts would recognize the same epi-
topes. CMVpos cCTL recognized typical epitopes while CB/
CMVneg cCTL recognized only atypical epitopes, suggesting
that the epitopes are naturally processed/presented by APCs.
Using deep TCR sequencing from the peripheral blood of CBT
recipients, the atypical epitope MLN was found in a similar
number of HLA-A2+ patients (6/9) than the typical epitope
(NLV) (5/9). These results reveal major, previously-unre-
ported differences in the naïve and memory CMV speciﬁc T-
cell repertoire but suggest that atypical epitopes may indeed
be important. Hence, we demonstrated that atypical epi-
topes are naturally presented by CMV-infected cells and are
now evaluating the clinical efﬁcacy of these CTL in recipients
of CBT.179
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Adoptive transfer of virus-speciﬁc T-cells (CTLs) from HLA
partially matched 3rdparty donors can effectively treat EBV,
CMV or Adv infections in recipients of HSCT from seroneg-
ative or cord blood donors. However, in vitro generated CTLs
selectively react against 1-3 immunodominant (ID) epitopes
(eps) presented by 1-2 HLA alleles. Therefore, to be effective,
it is critical that administered CTLs respond to eps presented
by HLA alleles shared by the recipient. To address this, we
established a bank of 123 GMP grade CMV-CTLs generated
using CMVpp65 peptide pool loaded autologous APCs. Each
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HLA allele.
The pool of CTL donors inherited HLA alleles in frequencies
similar to those in caucasian and black populations, with
certain alleles overrepresented. In 55% of the CTL lines, the ID
T-cell response (TCr) was restricted (restr.) by 3 HLA alleles:
A0201(25%), B0702(21%) and B 3501-11(9%); 45% of CTL lines
were restr. by other class-I alleles, and 17/123(14%) were
restr. by class-II alleles. Certain CMVpp65 15 mers contained
overlapping eps presented by both class-I and class-II, which
elicitedmore robust TCr. CTLs from all B0702+ donors (26/26)
were restr. by B0702. In comparison, CTLs from 30/39(77%)
A0201+ donors and 9/19 (47%) HLA B3501-11+ donors were
restr. by A0201 and B3501-11 respectively. Donors co-
inheriting A0201 and B 0702 (9/9) universally demonstrated
B0702 restr. ID TCr. In comparison, 11/12 (91.6%) donors co-
inheriting A0201 and B 4401-04 demonstrated HLA A0201
restr. CTLs. Strikingly, only 1/123 and 0/123 A1101+ and
A0301+ donors respectively demonstrated CTLs restr. by
these commonly inherited class eI alleles. This analysis thus
indicates an immunodominance hierarchy for CMVpp65 eps
and their presenting HLA alleles. In a series of 239 MUD, 137
MMUD, and 100 DUCB consecutive HSCT at MSKCC, we could
identify an immediately available CMVpp65 speciﬁc CTL line
matched with the patient at 2-3 alleles and restr. by a shared
HLA allele in this GMP-CTL bank in 86%, 89% and 80% cases
respectively. This CTL bank thus provides a clinical reagent
for the treatment of CMV infections in HSCT recipients. The
delineated immunodominance hierarchy for CMVpp65 may
also facilitate selection of an appropriately restr. CTL line for
treatment with predicted activity in the recipient. We can
also successfully generate CMV-CTLs against subdominant
CMVpp65 eps presented prevalent HLA alleles using a panel
of artiﬁcial antigen presenting cells (AAPCs). Expansion of
this bank with CTLs generated with AAPCs can broaden its
applicability to almost all HSCT recipients.180
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Lymphodepletion before adoptive cell transfer (ACT) can
enhance anti-tumor responses by increasing access to ho-
meostatic cytokines and by depressing the numbers of reg-
ulatory cells. However, the lymphodepleted recipient is at
risk for morbidity and mortality from pathogens. Indeed,
opportunistic invasive fungal infection (IFI) by Aspergillus sp.
results in a 60 to 85% in patients undergoing hematopoietic
stem-cell transplantation. Antifungal agents such as poly-
enes, triazoles, and echinocandins can be rendered ineffec-
tive due to shifts in fungal epidemiology, emergence of drug
resistant strains, and attendant toxicities in the recipients.
Thus, other strategies are being developed that target fungi.
Clinical-grade T cells genetically modiﬁed to express
chimeric antigen receptors (CARs) have been successfully
used to redirect speciﬁcity to target tumor-associated anti-
gens. We and others have infused CD19-speciﬁc T cells inpatients undergoing HSCT for investigational treatment of B-
cell malignancies. This provides a platform to expand the role
of adoptive immunotherapy to also target IFI.We adapted the
pattern-recognition receptor Dectin-1 to activate T cells via
chimeric CD28 and CD3-z (designated D-CAR) upon binding
with carbohydrate cell wall in Aspergillus germlings. The D-
CAR+ T cells exhibited speciﬁcity for b-1,3-gucan and
inhibited hyphal growth of Aspergillus. The D-CAR was then
expressed with our CD19-speciﬁc CAR (designated
CD19RCD28) which is currently used in clinical trials. Our
existing manufacturing platform was readily adapted to
electro-transfer plasmids from the Sleeping Beauty (SB) sys-
tem. Clinical-grade CD19-speciﬁc CAR+ T cells are produced
after introducing two DNA plasmids coding for transposon
(CD19RCD28) and transposase (SB11). The synchronous
electro-transfer of a third SB-derived DNA plasmid coding for
D-CAR resulted in CD19RCD28+D-CAR+ T cells. The resultant
genetically modiﬁed T cells can target both CD19+ malignant
B cells and Aspergillus. Generating CD19-speciﬁc T cells with
multiple speciﬁcities will enable introduced fungal immu-
nity to be long-lived and provides a foundation for engi-
neering an immune response with that can target multiple
antigens, such as to prevent the emergence of antigen-
escape variants.181
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Adoptive transfer of ag speciﬁc T-cells can effectively eradi-
cate viral infections and tumors. T-cells can be targeted to
speciﬁc ags expressed on tumor cells by genetic modiﬁcation
to express chimeric ag receptors (CARs); which are fusion
proteins incorporating an ag recognition moiety (ab) and T-
cell activation domains. Human T-cells genetically modiﬁed
to express a CD19-targeted CAR have been demonstrated to
successfully eradicate CD19+ B cell malignancies in patients
with refractory disease. The CARs developed thus far have
been directed against native cell-surface antigens, such as
CD19, that are recognized through antibody-derived anti-
gen-binding motifs, independent of antigen processing or
MHC-restricted presentation. However, tumor associated
intracellular self ags such as WT-1 require processing
following which antigenic epitopes are presented on the
tumor cell surface in complex with HLA class-I or class-II. A
strategy for targeting T-cells to speciﬁc peptide epitopes of
such self ags expressed on tumor cells involves genetically
introducing TCR mimic CARs containing a scFv ab directed
against the speciﬁc peptide-MHC complexes. CARs contain-
ing a Fab directed against an HLA-A0201-NY-ESO-1 epitope
have been generated, but functional data is lacking. We
generated a TCR-like CAR containing a scFv speciﬁc for an
HLA/peptide complex; the WT-1 RMFPNAPYL peptide pre-
sented by HLA-A0201 (A2-RMF CAR). The original A2-RMF
